( S ( NP-SBJ ( NNP Mr. ) ( NNP Sweig ) ) ( VP ( VBD estimated ) ( SBAR ( IN that ) ( S ( NP-SBJ-1 ( NP ( NP ( NNP Merck ) ( POS 's ) ) ( NN profit ) ) ( PP ( IN for ) ( NP ( DT the ) ( NN quarter ) ) ) ) ( VP ( VBD rose ) ( PP-EXT ( IN by ) ( NP ( QP ( RB about ) ( CD 22 ) ) ( NN % ) ) ) ( S-ADV ( VP ( VBN propelled ) ( PP ( IN by ) ( NP-LGS ( NP ( NNS sales ) ) ( PP ( IN of ) ( NP ( NP ( PRP$ its ) ( NN line-up ) ) ( PP ( IN of ) ( NP ( NP ( JJ fast-growing ) ( NN prescription ) ( NNS drugs ) ) ( PP ( VBG including ) ( NP ( NP ( NP ( PRP$ its ) ( JJ anti-cholesterol ) ( NN drug ) ) ( NP ( NNP Mevacor ) ) ) ( NP ( NP ( DT a ) ( JJ high ) ( NN blood ) ( NN pressure ) ( NN medicine ) ) ( NP ( NNP Vasotec ) ) ) ( NP ( NP ( NNP Primaxin ) ) ( NP ( DT an ) ( NN antibiotic ) ) ) ( CC and ) ( NP ( NP ( NNP Pepcid ) ) ( NP ( DT an ) ( JJ anti-ulcer ) ( NN medication ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )